Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nat Commun. 2020 Oct 21;11(1):5327. doi: 10.1038/s41467-020-19119-8.
Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment resistance. Here, using a single-cell DNA sequencing, we report the clonal architecture and mutational histories of 123 acute myeloid leukemia (AML) patients. The single-cell data reveals cell-level mutation co-occurrence and enables reconstruction of mutational histories characterized by linear and branching patterns of clonal evolution, with the latter including convergent evolution. Through xenotransplantion, we show leukemia initiating capabilities of individual subclones evolving in parallel. Also, by simultaneous single-cell DNA and cell surface protein analysis, we illustrate both genetic and phenotypic evolution in AML. Lastly, single-cell analysis of longitudinal samples reveals underlying evolutionary process of therapeutic resistance. Together, these data unravel clonal diversity and evolution patterns of AML, and highlight their clinical relevance in the era of precision medicine.
克隆多样性是癌症细胞进化的结果,这种进化受到达尔文选择的驱动。精确描述克隆结构对于理解肿瘤发展的进化历史及其与治疗耐药性的关系至关重要。在这里,我们使用单细胞 DNA 测序,报告了 123 例急性髓系白血病 (AML) 患者的克隆结构和突变历史。单细胞数据揭示了细胞水平的突变共发生,并能够重建以克隆进化的线性和分支模式为特征的突变历史,其中包括趋同进化。通过异种移植,我们显示了在平行进化的单个亚克隆中具有白血病起始能力。此外,通过同时进行单细胞 DNA 和细胞表面蛋白分析,我们说明了 AML 中的遗传和表型进化。最后,对纵向样本的单细胞分析揭示了治疗耐药性的潜在进化过程。总之,这些数据揭示了 AML 的克隆多样性和进化模式,并强调了它们在精准医疗时代的临床相关性。